UCB (UCBJF) recently reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against the approval of Xyrem for the treatment of fibromyalgia syndrome in adults.
We note that Xyrem is already marketed in the European Union (EU) for the treatment of narcolepsy with cataplexy in adults. UCB markets the drug in the EU under a license from Jazz Pharmaceuticals Inc. http://www.zacks.com/stock/news/49378/UCB+Faces+Setback
We note that Xyrem is already marketed in the European Union (EU) for the treatment of narcolepsy with cataplexy in adults. UCB markets the drug in the EU under a license from Jazz Pharmaceuticals Inc. http://www.zacks.com/stock/news/49378/UCB+Faces+Setback
No comments:
Post a Comment